

Clinical trials of poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in patients with BRCA mutation

TrialResults-center www.trialresultscenter.org

1 PARP inhibitors

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---------------------------------|
| niraparib vs placebo | | | |
| ENGOT-OV16/NOVA gBRCA, 2017 [NCT01847274] n=138/65 follow-up: | niraparib (300 mg) once daily as maintenance treatment versus placebo | patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation | Parallel groups double-blind |
| olaparib vs placebo | | | |
| SOLO2/ENGOT-Ov21 [NCT01874353] n=196/99 follow-up: | olaparib 300 mg in two 150 mg tablets, twice daily versus placebo | patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation | double-blind international |

References

ENGOT-OV16/NOVA gBRCA, 2017:

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Drum A, Tinker AV, du Bois A, Gonzalez-Martn A, Follana P, Benigno B, Rosenberg P, Gilb Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375:2154-2164 [[27717299](#)]

SOLO2/ENGOT-Ov21, :

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;: [[28754483](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.